Stipple Bio emerged from stealth with a $100 million Series A financing to advance STP-100, an antibody-drug conjugate targeting an undisclosed tumor antigen, and to scale its Pointillist discovery platform. The company’s approach focuses on epitope features driven by post-translational modifications, protein conformation changes, or mis-location rather than solely on overexpressed targets. Stipple plans to move STP-100 into clinical testing in early 2027 and aims to identify additional precision oncology programs with a “high therapeutic index” profile. The financing positions the company to broaden target discovery and prepare CMC and clinical readiness activities. For investors, the round reflects continued appetite for ADC and target-selection innovation—particularly platforms that promise differentiation beyond crowded surface-marker strategies.